Skip to main content
main-content

Medicine Matters oncology

Research news

27-06-2018 | Non-small cell lung cancer | ASCO 2018 | News

KEYNOTE-042: Pembrolizumab monotherapy supported for PD-L1-positive advanced NSCLC

Overall survival is significantly longer with single-agent pembrolizumab than with platinum-based chemotherapy in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer that has programmed cell death ligand 1 expression levels of at least 1%, according to the KEYNOTE-042 results.

26-06-2018 | Chemoprevention | ASCO 2018 | News

Chemoprevention with high-dose PPIs, aspirin an option for Barrett’s esophagus patients

Treatment with high-dose proton pump inhibitors and aspirin, especially when taken together, could prevent the progression of Barrett’s esophagus, trial results suggest.

25-06-2018 | Non-small cell lung cancer | ASCO 2018 | News

Support for adding atezolizumab to chemotherapy in advanced squamous NSCLC

Results from the IMpower131 trial show that patients with stage IV squamous non-small-cell lung cancer derive a significant progression-free survival benefit from combining atezolizumab with chemotherapy.

Expert interviews

14-06-2018 | Lung cancer | ASCO 2018 | Video

Expert commentary: Lung cancer highlights, including the KEYNOTE-042 and CCGA studies

ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Neoadjuvant chemoradiotherapy beneficial for resectable pancreatic cancer

Preliminary findings from the PREOPANC -1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46)

Watch the accompanying expert commentary.

08-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: An update from ASCO 2018 on targeted therapies in lung cancer

Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Adjuvant mFOLFIRINOX shows benefits over gemcitabine in pancreatic cancer

Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58).

Read the related news story

Watch the accompanying expert commentary

07-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: Lung cancer research from ASCO 2018

Watch this video to find out which studies reported at the ASCO Annual Meeting 2018 caught the interest of Advisory board member Lecia Sequist. She also talks about her own research presented at the conference (6:38).

06-06-2018 | Gastrointestinal cancers | ASCO 2018 | Video

Expert commentary: GI highlights including the PRODIGE 7, PRODIGE 24, and PREOPANC trials

ASCO expert Andrew Epstein gives his account of some of the key trial findings in  gastointestinal cancer from this year's meeting (9:05).

06-06-2018 | Esophageal cancer | ASCO 2018 | Video

Researcher comment: Shedding light on the use of PPIs and aspirin in patients with Barrett’s esophagus

Janusz Jankowski discusses his team's findings from the AspECT study on the chemoprevention efficacy and safety of aspirin and esomeprazole in esophageal cancer (7:42). 

03-06-2018 | Prostate cancer | ASCO 2018 | Video

Expert commentary: Unpicking the relationship between prostate cancer treatment efficacy, survival and race

ASCO Expert Robert Dreicer reviews two studies looking at differences in survival rates between Black and White men with metastatic castration-resistant prostate cancer (3:16). 

Read the accompanying news story here.

03-06-2018 | Head and neck cancers | ASCO 2018 | Video

Expert commentary: Are women with head and neck cancer undertreated?

ASCO expert Joshua Jones comments on the outcomes of an analysis of cancer registry data from a California Hospital system that highlights a disparity in intensive treatment between men and women with head and neck cancer (2:57).

Read the accompanying news story here.

image credits